Compare Humana Inc (HUM) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Roundhill Magnificent Seven ETF — how do they compare? Humana Inc trades at $437.2 (market cap $47.61B), while Roundhill Magnificent Seven ETF trades at $73.34 (market cap $5.84B). The key difference: Humana Inc is far larger — about 8.2× Roundhill Magnificent Seven ETF's market cap, and Humana Inc pays a 0.89% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| HUM | MAGS | |
|---|---|---|
Market Cap | $47.61B | $5.84B |
Volume | 1,827,332 | 1,765,091 |
Sector | Health | Sector/Thematic |
52-Week High | $409.85 | $73.90 |
52-Week Low | $163.67 | $55.39 |
Typical Hold Time | 53 Days | 36 Days |
Enterprise Value | $54.97B | — |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.69, down 0.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides equal-weighted exposure to seven mega-cap tech leaders and has delivered 181% returns since launch, though it trails the S&P 500 in 2026 with just 2% YTD gains. Recent news highlights AI-driven momentum but also concerns about the 'Magnificent Seven' theme fracturing as capital spending pressures dividends and buybacks.
The outlook remains cautiously optimistic given AI supercycle potential, but investors face concentration risk in tech and underperformance versus broader markets. Key risks include aggressive AI spending impacting cash flows and shifting investor preference toward semiconductors. Analyst sentiment is mixed, balancing long-term growth prospects against near-term valuation concerns and market rotation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
